ProImmune Ltd, a global leader in immunological reagents and services, announced the launch of Mastering Immunity 2026 - ...

Sanofi's acquisition of Dynavax, valued at $2.2 billion, aims to enhance its vaccine portfolio, including a promising shingles vaccine candidate, Z-1018. Z-1018 has demonstrated comparable ...

Scientists working for Novartis have taken a step forward in better understanding how new classes of biological drugs might affect patients’ immune systems. Paul Wassmann, PhD senior principal ...

This is an observer-blinded, three-arms study in 376 patients in Chinese individuals aged from 18 to 55 years old who had previously received three doses COVID-19 vaccine. Immunogenicity in terms of ...

Assessing immunogenicity is a cornerstone of modern drug development, especially for biologics and vaccines. Understanding how the immune system interacts with therapeutic agents is essential to ...

As biologics and biosimilars continue to reshape oncology, ensuring their safety and efficacy remains a top priority. In this expert-driven report, Cerba Research examines the latest advancements in ...

Background: This study (NCT00383123) compared the immunogenicity and safety of 2 trivalent inactivated influenza vaccines: Fluarix [GlaxoSmithKline (study vaccine)] and Fluzone [Sanofi Pasteur ...

Explore the safety and efficacy of switching to etanercept biosimilars, backed by clinical trials and real-world evidence for ...

Symposium brings together global leaders in immunogenicity to connect with China's rapidly evolving pharmaceutical development landscape Speakers include thought leaders in biotherapeutics ...